Will Novo’s LEADER Trial Move GLP-1 To The Front Line In High-Risk Diabetes?
This article was originally published in The Pink Sheet Daily
Novo Nordisk sets its sights on GLP-1 expansion after Victoza scores in CV outcomes trial, but docs want the full dataset to understand the robustness and implications of results.
You may also be interested in...
Meta-analysis published in JAMA suggests registry-based studies could be alternative to large cardiovascular outcomes trials.
FDA’s complete response letter for the cardiovascular risk reduction claim for Zetia/Vytorin was expected, but what will this mean for sponsors of drugs with other mechanisms, like PCSK9?
ELIXA trial results show neither increased nor decreased risk of major adverse cardiovascular events; Sanofi's diabetes drug, still unapproved in the U.S., becomes the only GLP-1 receptor agonist with CV outcomes data.